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1. Introduction 
1.1. Epidemiology of non-ST-Elevation acute coronary syndrome           
(NST-ACS) 
Over the years of 2005-2009 the proportion of patients suffering an acute coronary 
syndrome (ACS) of all hospital admissions stayed constant at about 1.3% throughout 
Germany. Whereas the number of patients admitted with ST-elevation myocardial 
infarction (STEMI) decreased, non-ST-elevation myocardial infarction (NSTEMI) 
patients increased continuously, especially throughout the age group of 65-89 years old. 
In 2009 61.5% of all ACS patients were considered NSTEMI, versus 50.5% in 2005 and 
showed to be consistently more frequent than STE-ACS since. 
Out of all ACS patients 76% were 60 years and beyond, with an average age of 71.9 
years in NSTEMI patients in 2009. There was a 1.7-higher rate of ACS in men than in 
women. In-hospital mortality is about 2-fold higher in STEMI patients, but at four years 
after admission there is a two-fold higher death rate in NSTE-ACS patients, likely 
caused by a higher rate of co-morbidities, like diabetes and renal failure in NSTE-ACS 
patients. [23, 11, 38, 63] There are similar numbers in the United States of America, 
where approximately 70% of the more than 780.000 ACS patients each year suffered an 
NSTE-ACS. [2] 
1.2. Pathophysiology of NSTE-ACS 
An ACS is caused by an imbalance between supply and demand of myocardial oxygen, 
leading to ischemia of muscle tissue, mostly as a result of a limited flow of oxygenated 
blood caused by an obstruction in the affected coronary artery. Most common (type I 
myocardial infarction) cause of obstruction in ACS is the deposition of cholesterol in 
the arteries leading to inflammatory processes and formation of an atherosclerotic 
plaque over time. Crucial for the development of plaques is an endothelial dysfunction, 
mostly caused by cardiovascular risk factors, like arterial hypertension, hyperlipidemia 
or diabetes mellitus. A higher permeability for lipoproteins results in low density 
lipoprotein (LDL) molecule accumulation within the sub-endothelium of the coronary 
artery and initiation of an inflammatory response. Oxidation of the accumulated LDL 
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leads to an amplification of the inflammation process and expression of adhesion 
molecules. Monocytes develop into macrophages and absorb the oxidized LDL particles 
via their „scavenger receptor“. Those cells are now called „foam cells“ and make up the 
early arteriosclerotic lesions known as „fatty streaks“. Fatty streaks usually don't cause 
symptoms. The inflammatory process induces a migration and proliferation of smooth 
muscle cells into the Intima and secretion of collagen, forming a cap around the core of 
the atheroma. A lower percentage of collagen in relation to the liquid, lipid rich core and 
destabilization of the cap by several molecules, like proteases produced by activated 
macrophages and T-cells results in a more vulnerable plaque and higher risk of rupture 
of the fibrous cap, responsible for approximately 60-70% of coronary thrombosis [28, 
35, 65]. The sudden disruption of a fibrous cap in the culprit lesion, acting as a stimulus 
for thrombogenesis is again triggering the formation of a thrombus resulting in an 
interruption of blood flow. Platelets play an important role in formation of early 
atherogenic lesions and thrombus formation. Platelets interact with sub-endothelial 
tissue to get activated and initiate tethering, rolling and adhesion. Following adhesion, 
platelets secrete pro-inflammatory and pro-coagulatory factors, like adenosine 
diphosphate (ADP). This process results in recruitment of monocytes, auto-activation of 
platelets and progress of atherogenesis. [25] 30% of ACS result from plaque erosion, 
meaning endothelial apoptosis leading to luminal thrombosis without communication 
with the necrotic core and is especially seen in young patients [35]. Most plaque 
ruptures (66%-78%) occur from vulnerable lesions with stenosis smaller than 50%, and 
only a small percentage of below 5% from lesions with above 70% stenosis of the 
coronary artery.  
Typ II myocardial infarctions are caused by other possible, but less common reasons for 
myocardial necrosis and include: coronary vasospasm, progressive luminal narrowing, 
inflammatory mechanisms like vasculitis, coronary dissection or extrinsic factors like 
anemia or severe hypotension. [53]  
Several cardiovascular risk factors have been described to significantly increase the risk 
of an ACS, including: high blood cholesterol, high blood pressure, positive family 
history, current smoking habit and diabetes mellitus. Typical symptoms of an ACS 
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include: prolonged anginal pain at rest being the most common clinical presentation 
with about 80% , de novo angina, destabilization of stable angina or post ACS angina. 
Atypical symptoms are often seen in female patients, elderly and patients suffering from 
diabetes or renal failure and include epigastric pain or isolated dyspnoe as an angina 
equivalent. Additional symptoms such as dyspnoe, sweating, nausea or syncope may 
also be present. [2, 56] 
A non ST-elevation-acute coronary syndrome is defined as a typical onset of symptoms 
with no persistent ST-elevation in the electrocardiogram (ECG). There may be ST-
depression, transient ST-elevation or T-wave inversions present, but not required for 
diagnosis. The umbrella term of NSTE-ACS is further subdivided, depending on 
additional laboratory work up. It includes:  
1. Non-ST-elevation myocardial infarction (NSTEMI), where cardiac 
biomarkers of necrosis, like troponin and CK/CK-MB are elevated and 
display a more severe injury of myocardial tissue. 
2.  Unstable angina pectoris (UAP), where cardiac biomarkers present negative. 
Flowchart 1: ACS definition by diagnostic means. 
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1.2. Treatment of a NSTE-ACS 
The in-hospital mortality of NSTEMI patients has declined between 2005 and 2009 to 
about 9.9% of all patients, showing a lower mortality rate in comparison to STEMI 
patients in which mortality increased to 12.2%. There was an increased use of coronary 
angiography throughout 2005 to 2009 in all ACS patients, so that in 2009, 55% of all 
NSTEMI patients underwent coronary angiography (CAG). Following CAG, 66.5% of 
NSTEMI patients underwent percutaneous coronary intervention (PCI) in 2009, out of 
which 95% were administered a intracoronary stent (55.8% being drug eluting stents 
(DES)). The data showed an increase in mortality in patients receiving PCI to 3.8% in 
NSTEMI patients, with a significantly lower rate in mortality, when using drug eluting 
stents vs. bare metal stents (BMS) (3.8% vs. 6.3% in 2009). In-hospital mortality of 
patients treated with anti-platelet agents was much lower at around 5% in NSTEMI 
patients. [23] 
1.2.1. Conservative therapy options 
Additional or singular administration of drugs in patients with NSTE-ACS have a 
prognostic and symptomatic value. They have shown to reduce the risk of further 
ischemic events, like stent stenosis, new myocardial infarction (MI) or stroke and have a 
positive influence with a significant reduction in mortality. Typically administered 
medication in patients being admitted with NSTE-ACS include a platelet aggregation 
inhibitor in form of acetylsalicylic acid (ASA) 150-300mg, often in combination with 
an ADP-receptor antagonist. A ß-receptor inhibitor is recommended in patients with 
ischemic symptoms and no contraindications. An anticoagulant like heparin, 
bivalirudine or a GPIIb/IIIa-inhibitor may be used additionally in patients with high risk 
profile. For the symptomatic release of angina complaints nitrolingual may be 
administered. Post-interventional, the patient receives a combination of a dual platelet 
inhibition, including ASA lifelong and an ADP-receptor antagonist for up to 12 months. 
Additionally, for secondary prevention a HMG-CoA reductase inhibitor (statins) to 
lower blood lipid levels, a ß-blocker and a angiotensin-converting-enzyme (ACE)-
inhibitor are prescribed. An anticoagulant like cumarine or one of the NOACs may 
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become required as part of a triple anticoagulant therapy in certain cases, like atrial 
fibrillation. [53] 
1.2.2. Invasive strategy options 
There have been several studies comparing outcomes of an early invasive treatment 
strategy versus a conservative strategy or more selective invasive strategy. Definition of 
the time span for early invasive strategy differed between studies making them harder to 
compare. Overall, there have been inconclusive findings on benefits and risks for 
NSTE-ACS patients depending on the strategy of treatment.  
The 2007 ICTUS-trial four year follow-up showed a higher risk for primary endpoints 
for the early invasive strategy and no significant difference in all-cause mortality 
between the two study groups. [29] Other studies, like 1999 FRIST II, 2001 Cannon et 
al., 2002 RITA-3-trial, 2006 Lindqvist et al., 2009 Mehta et al. and 2013 Tekin et al. all 
evaluated data, that suggested a significant reduction of their defined primary endpoint 
in an early invasive strategy in NSTE-ACS patients. 
The evaluation of a benefit on overall mortality between study groups differed among 
these studies. Only Mehta et al. and Tekin et al. showed a significant reduction in all-
cause mortality in patients receiving an early invasive strategy. Lindqvist et al. showed a 
benefit in mortality for patients receiving early invasive treatment, only when the 
patients were younger than 70 years old. [43, 62] FIRST-II, Cannon et al., the RITA-3-
trial and the ICUTS-trial four year follow-up all showed no significant difference in 
mortality between both strategies. [11, 30, 36, 29, 22] 
Most of the studies included an evaluation of the risk of major bleeding incidences to 
analyze adverse effects of an early therapy option. Cannon at al. showed no significant 
increase in thrombolysis in myocardial infarction (TIMI) major bleeding, but the 
RITA-3-trial and the ICTUS-trial-4 year follow-up showed a significant higher rate of 
major bleeding events in patients of the early invasive group. [11, 30, 29] 
2016 Fanning et al. analyzed eight prospective randomized controlled trials and 
compared clinical outcomes of a routine invasive versus a selective invasive strategy in 
NSTE-ACS patients. The data showed no significant benefit to all-cause mortality for 
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the routine invasive strategy, but it did show a risk reduction for MI, refractory angina 
and re-hospitalization. Patients receiving a routine invasive strategy showed a higher 
rate in post interventional bleeding events and an increased risk for procedural-related 
MI. Therefore Fanning et al. came to the overall conclusion to support a more selective 
approach for the use of invasive strategy in NSTE-ACS patients. [19] 
The European Society of Cardiology (ESC), just like Fanning at al., concludes in their 
2015 NSTEMI guideline that there is no significant benefit to an overall 
recommendation for early invasive strategies for all incoming patients suffering a 
NSTE-ACS alike. They rather recommend an early risk stratification at point of 
admission of each individual and initiate an invasive strategy, if eligible, depending on 
that risk stratification as explained in the segment below. The treatment and the timing 
of treatment can be individualized to minimize the risk of unnecessary adverse bleeding 
events and decrease the occurrence of primary endpoints and overall mortality. [53] 
1.2.3. Risk stratification 
Treatment possibilities and timing recommendations of invasive strategies for incoming 
patients suffering from NSTE-ACS differ depending on their initial risk stratification. 
Therefore a careful assessment of risks and benefits of an invasive strategy for each 
individual should be performed and evaluated at time of presentation. The risk 
stratification classifies four subgroups of risk criteria with decreasing severity from very 
high risk to high risk to intermediate risk and low risk (Table 1). Presentation of these 
different risk criteria in patients determine the time span and necessity of an invasive 
treatment strategy. [2] 
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Table 1: NSTE-ACS risk stratification criteria. 
Invasive coronary angiography (CAG) remains the main management strategy for 
NSTE-ACS patients in order to confirm and identify culprit lesions and therefore 
establish the indication for PCI treatment. CAG is a minimal invasive procedure that 
uses a radiocontrast agent, which is injected into the contrary arteries via a catheter, that 
is inserted into the artery via a mostly radial or femoral access site, and guided to the 
opening of the coronary arteries under x-ray control. The contrast material is injected 
into the coronary arteries. Using X-ray imaging the blood flow can be visualized on a 
monitor. Coronary stenosis therefore can be identified as a narrowing or complete 
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Very-High Risk High Risk Intermediate Risk Low Risk
Hemodynamic 
instability or 
cardiogenic shock
Rise or fall in 
cardiac troponin 
compatible with MI
Diabetes mellitus
Any characteristics 
not mentioned
Recurrent or 
ongoing chest pain 
refractory to 
medical treatment
Dynamic ST- or T-
wave changes 
(symptomatic or 
silent)
Renal insufficiency 
(GFR < 60mL/Min)
Life-threatening 
arrhythmias or 
cardiac arrest
GRACE score 
>140
LVEF <40% or 
congestive heart 
failure
Mechanical 
complications
Early post-
infarction angina
Acute heart failure Prior PCI
Recurrent dynamic 
ST-T-wave 
changes, 
particularly with 
intermittent ST-
elevation
Prior CABG
GRACE risk score  
> 109 and < 140
obstruction of the vessel. Alternative, less invasive approaches to CAG, like CT-
angiography may be used for diagnosis in patients with a high risk profile or critical 
contraindications for CAG. The time window for CAG in NSTEMI patients is defined 
by the initial risk stratification. The 2015 European Society of Cardiology-Guidelines 
classify four different categories with different time windows on when to perform CAG. 
Patients who meet at least one of the very-high risk criteria as defined above should 
receive CAG as soon as possible, but at least within two hours. When meeting at least 
one of the high risk criteria, CAG should be performed within 24 hours. The time 
window is expanded to 72 hours, when the patient meets at least one of the intermediate 
risk criteria category. For patients, who do not meet any of these criteria an invasive 
strategy is not recommended. [53] 
Flowchart 2: Risk stratification system for treatment decision. 
Percutaneous coronary intervention, when indicated, usually directly follows the CAG 
to treat stenosis and restore blood flow to the myocardial muscle tissue. Treatment by 
PCI can involve different procedure options to minimize coronary stenosis. Balloon 
angioplasty, a procedure that uses the inflation of a balloon inside the blockage of the 
artery to compress the atherosclerotic plaque and expand the artery, is the most 
commonly used procedure. An advanced development is the drug eluting balloon 
(DEB), that is coated with an anti proliferative substance (for example Paclitaxel) which 
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Risk 
LowVery high Intermediate High
Non-invasive
Immediately 
invasive (2 h)
Invasive 
(< 72 h)
Early invasive 
(< 24 h)
is instantly released at the site of stenosis and is supposed to lower the risk of re-
stenosis. Additional to widening the stenosis via ballon, the implantation of a stent into 
the obstructed area of the coronary artery is often indicated. A stent is implanted to keep 
the coronary artery open after ballooning. There are different types of stent material 
regularly used during PCI. Bare metal stents provide a mechanical framework and are 
not specifically coated. Drug eluting stents are coated with an anti-proliferative 
substance such as Paclitaxel, Everolismus or Sirolismus among others to slow down 
endothelialization of the stent and reduce the risk of in-stent restenosis. This process 
increases the risk of stent thrombosis and makes a prolonged usage of a ADP-P2Y12-
inhibitor necessary. [4] 
1.3. P2Y12-inhibitors 
Prior to percutaneous coronary intervention, incoming patients suffering a NSTE-ACS 
receive a loading dose of an ADP-P2Y12-inhibitor, as for example clopidogrel 300mg/
600mg or ticagrelor 180 mg as part of a dual platelet inhibition in combination with 
Aspirin to reduce the risk of thrombotic events and life threatening stent thrombosis. 
1.3.1. Characteristics of P2Y12-inhibitors 
Adenosine diphosphate (ADP) is soluble activator of platelet activation and 
aggregation. It binds a G-protein coupled receptor (P2Y) and results in a shape change 
of the platelet and secretion of vasoactive and procoagulant substances. Those 
substances further enforce platelet activation and coagulation. P2Y12-inhibitors prevent 
ADP from blinding the receptor site and starting the intracellular signaling process that 
results in further coagulation.  
There are two groups of P2Y12-inhibitors most commonly used: 
1. Thienopyridines, like clopidogrel and prasugrel, are irreversible inhibitors of 
the ADP-P2Y12-receptor. 
2. Cyclopentyl-triazolo-pyrimidine, like ticagrelor, is a direct and reversible 
ADP-receptor antagonist.  
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Both types of P2Y12-inhibitors interfere with the ADP-induced platelet aggregation, 
therefore causing a reduction in ischemic events, but also an increased risk of adverse 
bleeding events. 
clopidogrel is a prodrug that needs to be converted into an active metabolite by 
cytochrom P450 (CYP)-enzymes and therefore has a delayed onset with a maximum 
inhibition effect after five to six days. Administering a loading dose of 300-600 mg of 
clopidogrel reduces the delayed onset to three to five hours, which is important in the 
treatment of NSTE-ACS.  
Prasugrel and ticagrelor are faster acting drugs with an onset of effect (50% inhibition 
of thrombotic aggregation) after about 30 minutes. Because of CYP-polymorphisms, 
clopidogrel also shows a substantial inter-individual variability. Platelet reactivity can 
be tested via ADP-Multiplate Analyzer to identify non-responders to clopidogrel. [12] 
1.3.2. Ticagrelor vs. clopidogrel 
Platelet aggregation seems to be more rapid and effective with less inter-individual 
variability with ticagrelor compared to clopidogrel. The DISPERSE-2 study showed 
that ticagrelor achieved greater levels of inhibition than clopidogrel in NSTE-ACS and 
no significant difference in major bleedings between the clopidogrel and the ticagrelor-
group [10]. The same results concluded by Wallentin et al. (PLATO trial) showing that 
ticagrelor significantly decreases the risk of primary endpoints in comparison to 
clopidogrel in patients with ACS. They also stated no significant difference in major 
bleedings seen between these two groups. Ticagrelor, as a reversible antagonist of ADP 
receptors, additionally has the advantage of a much more rapid termination of effect on 
platelet aggregation and therefore faster management in treatment of an adverse 
bleeding complication. [66] 
1.3.3. Prasugrel vs. clopidogrel 
A 2007 study comparing outcomes and adverse effects in patients with ACS and 
scheduled PCI showed a significant reduction for ischemic events, when loaded and 
use of post interventional treatment with prasugrel versus clopidogrel. This association 
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was shown for stent thrombosis, myocardial infarction and urgent revascularization. The 
study also showed a significant higher rate of major and fatal bleeding complications 
throughout the prasugrel group, therefore suggesting a careful assessment of risks and 
benefits for each individual [68]. The 2014 ACCOAST-PCI study further supports these 
findings on the increase in adverse bleeding incidences following treatment with 
prasugrel, but could show no significant decrease in ischemic events. The cohort of the 
ACCOST-PCI study was limited to NSTEMI patients and suggest deferring the 
treatment with prasugrel until a decision about revascularization is made. [47] 
1.3.4. Need of P2Y12-inhibitor as pre-treatment strategy 
In regard to patients with ST-Elevation Myocardial Infarction (STEMI) the 2001 PCI-
CLARITY-Study was able to show a significant decrease in cardiovascular death, MI 
and stroke in patients pretreated with clopidogrel. Also, there was no increase in TIMI 
major or minor bleeding recorded, supporting a strategy of early and routine use of 
clopidogrel ad hoc treatment in all STEMI patients [54]. Therefore the 2013 AHA/
ACCF guidelines for the management of STEMI state a class-I-recommendation and a 
B-level of evidence for the use of a loading with clopidogrel, prasugrel or ticagrelor as 
well as long-term treatment with either one of these [46]. Looking at the treatment of 
NSTE-ACS patients, it seems that studies and guidelines are not as conclusively as they 
are for the treatment of STEMI, especially in regard to the timing of P2Y12-inhibitors. 
1.3.5. Guidelines on P2Y12-inhibitors 
The American Heart Association and the American College of Cardiology don't 
recommend the „upfront-use“ of prasugrel in patients with NSTE-ACS in the 2014 
AHA/ACC Guidelines following the findings of the ACCOAST-study. They do give a 
class I-recommendation grade and an A-level of evidence for an initial loading dose of 
300-600 mg clopidogrel in NSTE-ACS patients. Also they have a class-I-
recommendation and an A-level of evidence for administering a loading dose of a 
P2Y12-receptor inhibitor before PCI, naming clopidogrel or ticagrelor as possible 
options [2]. The 2015 European society of cardiology (ESC) guidelines for the 
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treatment of NST-ACS make no recommendation for or against the ad hoc usage of a 
pretreatment with clopidogrel or ticagrelor, hence no studies for the optimal timing of 
administration are available. But they also state a class-I recommendation with an A-
level of evidence for the addition of a P2Y12-inhibitor to Aspirin as a loading dose as 
well as long-term administration. Ticagrelor or prasugrel are recommended to all 
patients with moderate or high-risk for ischemic events, prasugrel to patients proceeding 
to PCI and clopidogrel only for patients who cannot receive ticagrelor, nor prasugrel. 
But just like the 2015 AHA/ACC-guidelines they are giving only a B-level of evidence 
and a class-III-recommendation for the usage of prasugrel as upfront pretreatment in 
NSTE-ACS patients without known coronary artery anatomy based on the findings of 
the ACCOAST-trial. [53] 
Pro 
Most guidelines at the time suggesting a beneficial use of pre-treatment and a 
continuous administration of clopidogrel following PCI, take into account that the 2001 
double blind, randomized PCI-CURE study showed, that in patients with NSTE-ACS 
undergoing PCI, the pre-treatment plus long-term administration of clopidogrel in 
combination to Aspirin was associated with a lower rate of cardiovascular death, 
myocardial infarction, or any revascularization by about a third. Additionally, it showed 
no significant increase in major, nor minor bleedings between the pre-treatment and the 
no-pre-treatment group. Therefore suggesting an overall benefit of a clopidogrel pre-
treatment-strategy in patients with NSTE-ACS undergoing PCI. [45] 
Following studies, including the 2001 Clopidogrel in Unstable Angina to Prevent 
Recurrent Events Trial Investigators, investigating the benefit and adverse effects of an 
upfront use of clopidogrel in patients concluded an association with a lower risk of 
major coronary events. They showed a reduced risk for death of cardiovascular cause, 
but not call cause mortality. In regard to bleeding events, studies differed from only 
showing an increase in minor bleedings in a 2012 systematic review to an increased risk 
for major bleedings in the CURRENT-OASIS-7 study. [7, 70, 44] 
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However by having a faster access to PCI following CAG nowadays and the more 
frequent usage and development of newer, more potent P2Y12-inhibitors, there is a 
need for updated studies to evaluate the overall benefit of ad-hoc therapy in NSTE-ACS 
patients. There are more current studies suggesting an at least more limited benefit of 
pre-treatment and a higher risk of bleeding by administering platelet aggregation 
inhibitors early on in NSTE-ACS patients. 
Contra 
The ACCOAST-PCI study has shown that patients receiving a prasugrel 30 mg loading 
dose as pre-treatment have a three-fold higher incidence of TIMI major bleeding and 
six-fold higher incidence of life threatening bleeding in comparison to patients receiving 
a placebo. The study also suggested that there is no significant benefit to a pre-treatment 
with prasugrel, when looking at the reduction of primary endpoints. [47] Bellemain-
Appaix et al. systematic review and meta-analysis of 2014 investigated the benefit of 
thienopyridine pretreatment in NSTEMI patients. It showed no significant reduction in 
any-cause death, cardiovascular death, stroke, myocardial infarction or urgent 
revascularization. However, it did state a significant association between the 
pretreatment with P2Y12-receptor antagonists and the occurrence of minor and major 
bleeding. This was shown for all NSTE-ACS patients and specifically for those patients 
receiving PCI, overall suggesting to reconsider the immediate pretreatment with P2Y12-
Inhibitors. [6] 
1.3.6. Timing of administration of P2Y12-inhibitors 
When evaluating the correct treatment strategy of NSTE-ACS patients to further limit 
the risk of bleeding without increasing the risk of ischemic events, it is crucial to 
consider the impact of timing of a possible anti platelet therapy in regard to diagnosis by 
CAG and final treatment by PCI. 
Manoukian et al. published in 2007 that the timing of aspirin, thienopyridine, and 
antithrombin administration related to angiography did not influence major bleeding.
[39] The multicentre trial PRAGUE-8-Study investigated primary endpoints and 
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bleeding complications between a group of patients with stable angina pectoris 
receiving 600 mg clopidogrel >6 h before CAG and a group of patients with stable 
angina pectoris (SAP) receiving 600 mg clopidogrel after CAG and only in case of PCI. 
The study showed that the pre-CAG-clopidogrel group had an increased risk of minor 
bleeding complications, especially in those receiving PCI. [2] The 2002 published 
Steinhubl et al. showed no significant reduction of incidence in death, myocardial 
infarction or urgent revascularization at 28 days in patients being administered a 
pretreatment loading dose of clopidogrel three to less than six hours before undergoing 
PCI. But patients being administered 300 mg clopidogrel at least six hours before PCI 
showed a relative risk reduction of about 38.6% in combined end points suggesting a 
benefit of early administration of clopidogrel. [58] 
The knowledge of the coronary anatomy and stenosis by CAG showed to be important, 
when identifying the need and benefit of an immediate PCI-treatment, even becoming 
part of the 2015 ESC guidelines, when looking at the recommendation for usage of 
prasugrel depending on wether the coronary anatomy is known. Nowadays PCI is 
usually being performed immediate after diagnosis of stenosis by coronary angiography. 
Considering the findings above, which suggest administration of anti-platelet 
medication as early as possible when undergoing PCI, an anti-platelet therapy needs to 
be administered in advance of CAG in order to reach its full effect at time of PCI. But 
this sequence of events further limits the chance to identify patients, who will not 
benefit from an ad-hoc P2Y12-receptor inhibitor treatment, but might even have an 
increased risk of bleeding and therefore calls for a new way to identify and evaluate 
patients with a high-risk for bleeding events, when administered pre-treatment anti-
platelet drugs. 
1.4. Bleeding complications 
When discussing the necessity versus the adverse effects of an early treatment of NSTE-
ACS patients with a P2Y12-inhibitor, it is important to know the likelihood of bleeding 
after PCI as well as the impact of the bleed on the overall outcome. Even though most 
patients (81.9%) with ACS undergoing PCI don't develop a major bleeding [33], 
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periprocedural bleeding is still one of the most frequent complications of PCI with 
reported incidences of major bleeding as high as 5.4%, close to the reported incidences 
of refractory ischemia, MI, or death. [39, 49, 33] Minor bleedings were recorded at 
12.7% of the patients during the study of Kinnaird et al., who also showed no 
significant association to antithrombotic treatment. [33] 
1.4.1. Known risk factors 
P2Y12-inhibitors 
Anti-thrombotic medication increases the risk in bleeding events, because of their 
desired effect on platelet aggregation. The ACCOST-PCI study, for example, showed 
that prasugrel has a significantly higher incidence in minor and major bleeding 
complications. [47, 68] 
Clinical factors 
Other Studies have shown age, sex, elevated creatinine, white blood cell count and 
anaemia as independent risk factors for bleeding in ACS patients. [40] Other predictors 
proved to be lower weight, heart rate, low systolic blood pressure and lower baseline 
hematocrit in NSTEMI patients. [61] 
1.4.2. Preventive measures 
Drug regime 
When expecting a higher risk for bleeding events in patients it is possible to change the 
regime of the medication used pre- and periinterventional. For example the usage of 
clopidogrel instead of the more potent prasugrel or ticagrelor, when expecting a risk in 
bleeding, because of its lower inhibition rate of the ADP receptor. Another possibility is 
the use of Bivalirudine, rather than Heparin and abandon the use of GPIIb/IIIa-receptor 
antagonists to further reduce the risk in bleeding. [60, 59, 32] 
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PCI-access site 
The use of a less susceptible access site to introduce the catheter is a common way to 
further prevent bleeding. The access site via radial artery should be preferred over the 
femoral artery, if possible. It significantly reduces access site complications, is easier to 
compress in case of bleeding and provides a more limited space for spreading, reducing 
the risk for major bleeding events. It also allows the mobility of the patient without 
increasing the risk of bleeding. The radial access site shows a significant reduction in 
mortality in patients with ACS after two years compared to femoral arterial access. [53, 
31, 1, 24] 
Postprocedual sealing systems 
Following coronary intervention a sealing system may be used in patients to reduce the 
risk of bleeding from the exit site of the catheter. Some studies have indicated a 
significantly shorter time to hemostasis and a higher reduction in local complications in 
comparison to manuell compression. These systems also show a risk of lower limb 
ischemia, arterial stenosis and device entrapment. [55, 34, 17] 
1.4.3. Impact of bleedings on outcome/mortality 
Mortality 
Non-coronary artery bypass graft (CABG)-related major bleeding is an independent risk 
factor for one-year mortality showing a significant increase in risk of death within and 
after 30 days. The 30-day mortality after major bleeding was six-fold higher than in 
patients without major bleeding events, which makes bleeding events a stronger 
independent risk factor than MI. [39] This was supported by further studies, all showing 
minor and even stronger major bleeding events to be significant independent risk factors 
for 30-day and one year mortality [41, 49, 33, 20] Further, the prognostic impact and 
risk of mortality was directly correlated to the severity of the bleeding. Only isolated 
hematoma showed no significant effect on mortality. [40, 20, 41, 16] For example, the 
bleeding academic research consortium (BARC) was able to observe an association 
between a BARC type three-bleeding, comparable to TIMI major and minor and the 
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global use of strategies to open occluded arteries (GUSTO) moderate and severe 
bleedings, and the two-year mortality. Within the BARC-type three patients, there was a 
correlation between severity of the subgroups and the mortality risk (3a<3b<3c). The 
shown association was regardless of the time passed after PCI, nor the regime of anti-
platelet-therapy used. [64] 
Ischemic events 
A significant increase in risk of ischemic and hemorrhagic stroke within 30-days 
following a major bleed could be shown. After 30-days there was a reduction in risk 
showing no significant increase for risk of stroke any longer. [16] Patients suffering 
major bleeding events had a three-fold higher rate of ischemic events in the first 30-day, 
significantly higher rates of MI, unplanned revascularization, a nearly six-fold higher 
risk for stent thrombosis. [39] Patients suffering a major bleeding had a significantly 
prolonged hospital stay. [39, 33] 
No impact 
Studies showed that CABG-related major bleeding did not significantly increase 
the risk of mortality and cardiac death, which may be interesting in the context of 
withholding antithrombotic therapy before knowing the necessity of CABG in 
ACS patients. [40, 41, 64] 
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1.5. Aims 
The 2014 ACCOAST-PCI study showed for NSTEMI patients undergoing PCI, that a 
pretreatment strategy with prasugrel was not associated with a significant benefit on 
ischemic events. Furthermore, they did show a significant increase in major and life-
threatening bleeding complications, when pretreated with prasugrel. This has led them 
to the conclusion to defer the pretreatment with prasugrel, which has been incorporated 
into the newer guidelines for NSTE-ACS therapy. Besides the ACCOAST-PCI study, 
there are several other studies analyzing the benefits and adverse effects of a 
pretreatment strategy in NSTE-ACS patients, coming to different conclusions. Up to 
date guidelines still support a general pretreatment strategy. 
The aim of this retrospective study of NSTE-ACS patients undergoing PCI after being 
pretreated with an ADP-antagonist, is to analyze the risk factors of post-interventional 
bleeding rates. We aimed to analyze usual clinical risk factors, timing and type of the 
loading with ADP-antagonist and platelet reactivity accessed by multiple electrode 
aggregometry (MEA). Furthermore, major adverse events following PCI were recorded. 
The objective of the evaluated risk profile was to categorize incoming patients by 
bleeding risk more accurately and directly at time of admission. Being able to categorize 
patients by their individual risk profile will then again help to decide whether an early 
preventive strategy may be indicated to avert adverse events and improve overall 
outcome. A preventive, more cautious approach may then be taken, as described above, 
in form of different medication being used, different arterial access site for catheter 
installation or the use of sealing systems. 
There is only little research on the timing of the loading with a P2Y12-inhibitor and its 
consequences on the probability of adverse events, which is why we also categorized 
patients into four different subgroups depending on their loading time. By doing so, we 
were hoping to evaluate differences in probability of bleeding incidences and primary 
endpoints depending on the time category of their pretreatment.  
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By adding a three months follow-up with all patients recording primary endpoints, we 
were also including the outcome into the overall analysis. This allowed us to compare 
outcomes between both cohorts, bleeding versus non-bleeding, but also between  the 
kinds of P2Y12-inhibitors administered and their different loading times. Having an 
assessment of the outcome, as well as the probability of adverse bleeding events, allows 
us to compare benefits and disadvantages of certain strategies to one another, leading to 
a more valid recommendation for treatment options.  
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2. Methods 
2.1. Study population  
The study was conducted as a retrospective analysis. The study population consisted of 
patients recruited in Tuebingen Platelet Investigative Consortium (TuePIC) trial in the 
department of cardiology at the university hospital of Tuebingen (UKT). From 2547 
patients admitted between 2011 to 2014, 439 patients were included into this study 
according to following criteria. 
Inclusion criteria 
Patients diagnosed with NSTE-ACS including NSTEMI and unstable angina pectoris 
(UAP), who received a P2Y12-inhibitor prior to PCI were included.  
Exclusion criteria 
Patients with ST-elevation myocardial infarction on admission or patients not receiving 
coronary angiography after diagnosis were not included into the study group.  
Patients suffering from NSTE-ACS, but not being administered an ADP-P2Y12-
inhibitor at all or only at the time of percutaneous coronary intervention were also 
excluded from the study. 
Patients data including clinical baseline characteristics, used P2Y12-receptor antagonist, 
follow-up (major adverse cardiac events (MACE) and bleeding events) and platelet 
function analysis were obtained from the TuePIC database and patients’ files. Data were 
anonymized for the analysis. The cohort was divided into two subgroups depending on 
documented bleeding occurrences following PCI. These events were retrospectively 
researched by browsing the TuePIC database, physician letters and other documentation 
by the UKT for each patient. The control group consists of 300 patients with NSTE-
ACS, who did not suffer any documented post-PCI bleeding event. 139 patients suffered 
a documented bleeding event within three months after PCI, meeting the TIMI-Bleeding 
Score, BARC-Classification and Gusto Score. 
For further evaluation of the effect of timing of the administration of the P2Y12-
inhibitor on the occurrence of post interventional bleeding, patients were stratified into 
four groups depending on the time of receiving a loading dose: The first subgroup 
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consisted of a total of 232 patients receiving a pre-treatment loading dose only. The 
second group included patients receiving a pre-treatment, as well as a loading at the 
time of PCI, consisting of 136 patients. The third group included all 26 patients, where 
the P2Y12-inhibitor was already part of their daily medication. The last group is made 
up of patients with a P2Y12-inhibitor as part of their daily medication, who additionally 
received a pre-treatment loading dose and includes 45 patients altogether. 
Flowchart 3: Categorization of cohorts and subgroups. 
28
NSTEMI or UAP 
439 patients
no bleeding 
300 patients
daily medication and  
pre-treatment loading 
28 patients
pre-treatment loading 
156 patients
daily medication of  
P2Y12-inhibitor 
15 patients
pre-treatment loading  
and at time of PCI 
101 patients
bleeding 
139 patients
daily medication and  
pre-treatment loading 
17 patients
pre-treatment loading 
76 patients
daily medication of  
P2Y12-inhibitor 
11 patients
pre-treatment loading  
and at time of PCI 
35 patients
2.2. Bleeding classification 
For better comparison of patients, we used three bleeding scores: TIMI, GUSTO and 
BARC. By the use of these scores, we were able to classify the severity of the bleed in 
all patients suffering a bleeding event following intervention (event group). Most 
bleeding events were not initially classified by the physicians in charge at the time of 
hospitalization. Therefore, the classification of severity was mostly done retrospectively, 
after research of clinical description, sonographic measurements and laboratory 
findings. 
2.2.1. TIMI bleeding classification 
The TIMI Bleeding Classification was developed to classify hemorrhage in STEMI 
patients and differs between non-CABG- and CABG-related bleeding. It consists of 
three categories with increasing severity, including minimal, minor and major. For non-
CABG related bleedings, as applicable for this cohort, it uses a combination of clinical 
observations, like overt signs and location of the bleed and fatal outcome. It also puts a 
big emphasis on laboratory data, especially drops in hemoglobin or/and hematocrit to 
evaluate the bleeding severity. [42, 9] The CABG-related classification uses 
localization, need for intervention, chest tube output and fatality of the bleed to classify 
the severity, but has not been used throughout this study cohort. 
The TIMI bleeding classification was developed on STEMI patients, which differs from 
our NSTEMI study group, but still gives us a valid comparison of hemorrhage severity 
between patients. 
2.2.2. GUSTO score 
The global use of strategies to open occluded arteries classification (GUSTO) is a 
clinically driven score that differentiates bleedings into three subgroups with increasing 
severity.  
Severe or life-threatening bleed consisting of intracerebral hemorrhage or resulting in 
substantial hemodynamic compromise requiring treatment. Moderate bleeding requiring 
blood transfusion, but not resulting in hemodynamic compromise and mild bleeding, 
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which does not meet the criteria above. It differs from other definitions, in that it doesn't 
take changes of hemoglobin into account. Because of this only clinically driven 
criterion, the severity tracks well with the risk of MI and death but shows a lack of 
objective standardization. [42, 51] 
The GUSTO-Score was developed in the fibrinolytic era and was done on STEMI 
patients, which again differs from the drug treatment and patient cohort within this 
study group. 
2.2.3. BARC-classification 
The score by the bleeding academic research consortium (BARC) classification was 
developed to standardize the assessment of bleeding events and use a numeric 
categorization with increasing severity of the bleed, instead of descriptive terms like 
major or minor bleeding, that are being used in other classification systems. However, 
in order to compare patient cohorts by the severity of the bleeding event, we chose to 
define each bleeding, categorized BARC three or higher as a „major bleeding“. The 
BARC score uses five categories to classify a bleed, which derive from a combination 
of clinically and laboratory based criteria that were intergraded from already exciting 
scores, like GUSTO and TIMI. [42, 64] Eikelboom et al. was able to show that the 
BARC classification presents the strongest correlation of the real clinical condition, 
when compared to TIMI and GUSTO bleeding scores, therefore suggesting the 
preference of the use of BARC over GUSTO and TIMI. [16] For the evaluation of 
outcomes, like MI or death following adverse bleeding complications, a study by Rao et 
al. showed that it seems to be more crucial to look at clinical criteria and the need for 
blood transfusion instead of laboratory findings. The increased risk of short or 
intermediated death or MI with an increasing severity in GUSTO bleeding complication 
in patients persisted after adjusting for transfusion. This was not true, when using the 
more laboratory driven TIMI bleeding score. Therefore, suggesting a higher correlation 
of outcome to clinical criteria versus laboratory findings. [51] 
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2.3. Risk scores 
Determination of the pre-treatment bleeding risk for each patient was done by using the 
ACUITY score and the CRUSADE score. Additionally we determined the mortality risk 
of each patient by applying the TIMI-risk score and the global registry of acute coronary 
events (GRACE) mortality score. 
2.3.1. Bleeding events 
ACUITY-HORIZON  
It is used to predict the risk for non-CABG related major bleedings in patients with ACS 
within 30 days. It uses seven independent predictors: female sex, advanced age, 
elevated serum creatinine and white blood cell count, anemia, presentation of STEMI/
NSTEMI or UAP and usage of antithrombotic medications in form of heparin + 
glycoprotein IIb/IIIa-inhibitor (GPI) or Bivalirudin. Depending on the score, the risk for 
bleeding is categorized into 4 different groups: low, moderate, high and very high with 
an increasing risk for major bleeding. It also showed a higher rate of bleeding 
complications in patients with STEMI than NSTEMI and again higher than in patients 
with UAP. [40] 
The ACUITY-HORIZON trials included STEMI patients additionally to NSTEMI and 
UAP, which is a different setting compared to our study cohort. But, more crucially it is 
derived from patients receiving either Bivalirudin or a GPI, which was rarely 
administered throughout our cohort and is not the standard form of treatment for 
NSTEMI. This may lead to a restricted use for this particular risk score in NSTEMI 
patients nowadays. 
CRUSADE 
A second risk score used for this study to predict the occurrence of bleeding is the 2009 
CRUSADE risk score. It was derived from a study on NSTEMI patients and is being 
used to predict the risk of in-hospital major bleeding. The score uses the patient 
characteristics age, heart rate, systolic blood pressure, hematocrit and creatinine 
clearance, as well as signs of CHF on admission, diabetes mellitus and prior vascular 
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disease, that showed to be significantly associated with a higher risk in bleeding events. 
[61] The added sum of weighted scores out of these eight predictors, ranges from one to 
100 and is divided into quintiles with increasing bleeding risk. Starting with a) very low 
with a score of below 21, b) low, with a score between 21 and 30, c) moderate, with a 
score of 31 to 40, d) high risk, with a score of 41 to 50 and d) very high risk, with a 
score of above 50. 
The CRUSADE risk score is derived from a cohort that is better comparable to our 
study group. Both cohorts consist of NSTEMI patients, even though we also included 
UAP patients. Differing from our own criteria, patients taking warfarin at home were 
excluded from the CRUSADE study. Anticoagulants are a common medication among 
patients and are known to result in an increased bleeding risk, making them an 
important factor to be analyzed, when trying to get a complete bleeding risk profile for 
the patient. Also the CRUSADE study did not look at cohorts depending on their 
pretreatment with a P2Y12-inhibitor and was only developed in regard to major 
bleedings. 
Accuracy of bleeding risk scores 
A 2015 meta-analysis of nine studies looking at the accuracy of bleeding scores in 
patients presenting with myocardial infarction showed that, when looking at all ACS 
patients, CRUSADE and ACUITY-Score performed similarly, when compared to 
GRACE. CRUSADE was the only one externally validated for NSTEMI.[51] 
2.3.2. Mortality 
TIMI risk score 
The 2001-developed score by Antman EM et al. UAP or NSTEMI patients aims at 
predicting the probability of ischemic events, like MI, urgent revascularization and all-
cause mortality. The study was able to identify seven significant predictors, including 
age, risk factors for coronary artery disease (CAD), known CAD, severe angina, use of 
Aspirin, ST-deviation ≥ 0.5 mm and elevated cardiac enzymes. [3] The results of the 
TIMI risk score are calculated by adding one point for each assessed risk factor. When 
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patients show a risk score of zero or one point, they should be further risk stratified. 
When showing higher risk scores, more aggressive intervention may be necessary.  
The TIMI risk score was derived from a similar cohort, including UAP and NSTEMI 
patients. But they did randomly assign either heparin/Fondaparinux therapy versus 
placebo and did not include different P2Y12-inhibitor regimes into account. Also, 
because of low incidence at trial, the TIMI risk score does not include heart failure, 
which is a significant risk factor for death, as shown by Granger et al. [26, 27] 
GRACE mortality score 
Developed in 2002 by Granger CB et al., it uses eight factors to evaluate the probability 
of all-cause death during hospitalization for all ACS patients. The highest increase in 
death was shown by the Killip-classification (two-fold), followed by age (1.7-fold), 
making them the most relevant predictors. Blood pressure, cardiac markers, cardiac 
arrest on admission, ST-segment deviation, heart rate and creatinine levels also showed 
to be significant predictors. The GRACE score seems to be a beneficial tool to predict 
all cause death in STEMI, NSTEMI and UAP patients, having shown no impact of the 
presence of ST-elevation for the determination of risk of death. [27] The GRACE risk 
score is divided into three different risk categories representing the probability of in-
hospital death. A score from 1 to 108 (low risk) correlates with an in-hospital death of 
below one percent, a score of 109 to 140 (intermediate risk) with one to three percent 
and a score of 141 to 372 (high risk) with above three precent. 
Differing from our study cohort, the GRACE cohort included all forms of ACS, 
including 39% of the patients being admitted with STEMI, and only a small fraction of 
the cohort was treated with clopidogrel. 
In 2004 the GRACE-6-months post discharge prediction model identified nine 
variables, again for all ACS patients, to predict all-cause mortality within six months of 
discharge. Equivalent to the 2002 GRACE mortality score, the calculated risk score is 
divided into risk categories correlating with the percentage of the 6-months post 
discharge mortality. The low risk category including a risk score of one to 88 correlates 
with a six-months mortality of below three percent, the intermediate risk (score of 89 to 
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118) with three to eight percent and the high risk category with a mortality of above 
eight percent for non-STE-ACS. [15] 
Accuracy of mortality risk scores 
In NSTE-ACS, quantitative assessment of ischemic risk by means of scores is superior 
to the clinical assessment alone. The GRACE risk score provides the most accurate 
stratification of risk, both on admission and at discharge. [53] The comparison of the 
risk scores TIMI, PURSUIT and GRACE in 2005 by Gonçalves et al. analyzed that out 
of these scores the GRACE risk score showed to have the best discriminatory accuracy 
for major adverse cardiac events, whereas the TIMI-risk score showed the lowest at 30-
days and one-year. For the long term prognosis all three scores showed higher 
accuracies. [26] Accordingly the 2015 ESC guideline for NSTEMI uses the GRACE 
risk score categorization, as one of the possible risk stratification criteria to evaluate the 
need and the necessary time window of an invasive strategy in NSTEMI patients, 
having a class-I-recommendation and a A-level of evidence. [53] 
2.4. Statistical analysis 
Continuous data are presented as mean ± SD, categorical variables are expressed as 
number (%). Equality of distribution of categorical variables between subgroups was 
analyzed by chi-squared test. For analysis of predictors for bleeding events univariate 
logistic regression analysis was used. In the analysis 
• Clinical observations: age, sex, body mass index (BMI) 
• Laboratory findings: renal insufficiency, troponin, CK/CK-MB (NSTEMI 
vs. UAP) 
• Echocardiographic data: heart insufficiency (LVEF) 
• Prior medical history: prior ACS or PCI/ACB-OP, diabetes mellitus, 
hypertension, hyperlipidemia 
• Prior drug intake: anticoagulants, P2Y12-inhibitors 
• Platelet function analysis: ADP-Multiplate data 
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• Pre- and peri-interventional therapy: treatment option, P2Y12-inhibitor 
loading therapy, change of ADP-antagonist, use of sealing system 
• Follow-up data: MACE at three months 
Factors with a significance level of p < 0.1 in univariate analysis were included into 
multivariate model. Multivariate analysis was then used to identify independent 
predictors of bleeding. For comparison of categorical and continuous data a two-sided 
p-value of < 0.05 was considered statistically significant. All statistical tests were 
performed with IBM SPSS Statistics software, version 21.0. 
2.4.1. Platelet function analysis 
Platelet function analysis was performed via ADP-Multiplate analyzer in order to 
integrate the platelet function into the evaluation of the individual bleeding risk of 
patients. Other platelet activators, that were also measured via Multiplate were not of 
high interest for the context of this study and therefore not further analyzed and 
evaluated. A total of 421 out of 439 patients (95,9%) received measurements of their 
platelet function.  
The P2Y12-receptor, on the surface of blood platelets, is one of the mechanisms used to 
regulate platelet aggregation. It is a G-protein coupled protein for ADP. After binding an 
ADP-molecule, it leads to platelet activation and supports the clotting process. 
Therefore, it can be used as a target for P2Y12-antagonists, like clopidogrel, prasugrel 
and ticagrelor, to prevent thromboembolism. Measurement of the platelet function via 
ADP-Multiplate analyzer shows the degree of inhibition reached by the administered 
P2Y12-inhibitor. It also allows classification of each patient, receiving a P2Y12-
inhibitor, in regard to their individual responsiveness to the administered medication. 
This is usually done, when administering clopidogrel. The patient is categorized as a) 
normal-responder, b) low-responder or c) non-responder correlating with an increasing 
risk for ischemic events in low- or non-responders and can be used as indication to 
change treatment protocol. On the other hand normal responders and patients with high 
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responsiveness of a certain platelet activator antagonist may show a higher risk for 
bleeding events. 
Functionality of the multiplate analyzer: 
The multiplate analyzer uses impedance aggregometry. It is a method, that continuously 
records the electrical impedance between two metal sensor electrodes inside the test 
cuvette. Adhesion and aggregation of platelets on the surface of these electrodes will 
result in change of impedance , which is continually recorded by the analyzer.  
The patient sample consists of whole blood and is primarily anticoagulated with the 
thrombin antagonist Hirudin. For this reason, after admission of the patient and consent 
to the study procedure, a blood panel was drawn for the laboratory work up as well as 
the multiplate analyzer. The sample is diluted with saline and incubated at 37 °C for 
about three minutes before adding the chosen platelet agonist. 
There are different inductors of platelet aggregation, which can each be evaluated 
individually via multiplate: 
• ASP-I-Test is conducted via the activator arachidonic acid and is typically 
influenced by the administration of ASA. 
• ADP-Test, where ADP is used as an activator and is affected by P2Y12-
inhibitors and is therefore the platelet function test of choice, evaluated in 
this study. 
• Thrombin receptor activating peptide (TRAP-6), which stimulates the 
thrombin receptor independently is used as negative and quality control of 
platelet aggregation. This is also why Hirudin must be used. The TRAP-6 
activator also includes the platelet inhibition by GPIIb/IIIa-antagonists and is 
therefore a necessary control, when evaluating platelet function. 
• COL-test using collagen as inductor of platelet aggregation. 
• RISTO-test using Ristocetin as platelet agonist. 
The patients blood was usually analyzed for all of the aggregation agonists mentioned 
above, except for the Ristocetin. For this particular study cohort however, only the 
36
ADP-test was of specific interest, because of its correlation to P2Y12-inhibitor 
administration. The chosen activator is added to the whole blood of the patient and 
allows the quantitative in vitro ascertainment of platelet aggregation by detecting 
changes in impedance over time. The results are usually depicted in form of a graph 
showing the change in impedance over time from which the area under the curve in [U] 
is calculated. This parameter is the most useful in assessing platelet function and was 
used within this study group. Further parameters are the maximum aggregation in [AU] 
showing as the maximum height of the curve and the velocity of aggregation in [U/
min]. 
Different factors may affect the result of the multiplate, including thrombocytopathy, 
thrombocytopenia and all medication influencing the platelet aggregation. The reference 
value for the ADP-test in non anti-coagulated whole blood sample is 57-113 U, which 
depicts the 5th to 95th percentile. When using anticoagulation in form of P2Y12-
inhibitors the value is expected to be lower. 
A 2009 cross validation of the multiple electrode aggregometry to different systems 
testing platelet function in patients came to the conclusion that the greatest signal 
magnitude for clopidogrel and Aspirin was found in multiplate analysis. [57] 
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2.5. Follow-up 
To evaluate possible short-term consequences on outcome we included a three months 
follow-up with each patient. This was done by phone call with the patient or close 
relatives, additionally to retrospectively checking newer physician letters and re-
hospitalizations at the hospital of Tuebingen (UKT). 
The following primary endpoints were included in the follow-up: 
• Stroke 
• Transient ischemic attack (TIA) 
• ACS 
• Stent thrombosis 
• Pulmonary embolism 
• Revascularization 
• Death 
All 439 patients received a three months follow-up. None was completely lost within 
this time span. 
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3. Results 
3.1. Baseline characteristics 
439 patients met the necessary criteria and were included into this study. Out of which 
174 patients (39.6%) were hospitalized because of UAP and 265 patients (60.4%) were 
diagnosed and treated for a NSTEMI. 
Baseline patients’ characteristics are shown in table 2. 69.7% of the patients are male 
and 30.3% female with an overall mean age of 68 years (CI 67 bis 69). 31.9% suffered 
from diabetes, 49.8% had hyperlipidemia, 35.1% were current smoker and 81.3% were 
previously diagnosed with hypertension. The mean body mass index (BMI) was 27.8 
kg/m2 (CI 27.4 - 28.3). Adipositas defined as BMI > 30 kg/m2 was seen in 27% of all 
patients. 
The mean left ventricular function (LVEF, %) was at 50.4% and the mean creatinine at 
1.1 mg/dL with a calculated mean GFR (Cockcroft-Gault) of 84.6 ml/min/1.73m2, 
representing a KDOQI stadium G2. Baseline medication showed that in 17.4% a 
P2Y12-inhibitor was already included and 9.3% of the patients used an anticoagulant. 
Prior MI was recorded in 29.1% and prior need of PCI in 36%. 
ADP-antagonists loading characteristics are shown in table 3. 80.9% of patients were 
administered or already taking clopidogrel, 14.4% were treated with ticagrelor and 4.8% 
with prasugrel. The combined group of newer ADP-antagonists made up 19.1%. 
Timing of the loading was done in 52.8% prior to PCI, in 31% prior and at time of PCI, 
10.3% already used a P2Y12-inhibitor and were loaded additionally at time of PCI and 
5.9% were only having the P2Y12-inhibitor already as premedication. 
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Baseline 
characteristics
Study cohort 
n = 439
Cohorts depending on 
bleeding occurrence 
p-value
Control group 
n = 300
Event group 
n = 139
Gender m/f (%) 69.7/30.3 71.7/28.3 65.5/34.5 0.214
Age (years) 68 (67-69) 67 70.6 3
BMI (mean) 27.8 
(27.4-28.3)
27.4 27.7 0.507
Adipositas BMI > 30 
(%)
26.9 25.5 28.3 0.508
Diabetes mellitus 
(%)
31.9 28.6 38.7 0.078
Hyperlipidemia (%) 49.2 49 51.5 0.708
Hypertension (%) 80.4 80.6 82.4 0.714
Current smoker (%) 34.9 37.5 30 0.127
GFR (mean) 84.6 89 80.2 0.060
GFR < 60% 35.7 28.5 34.1 0.031
Left ventricular 
function (mean, %)
50.4 51.9 48.8
LVEF < 55% 48.7 48.2 50.0 0.371
UAP vs NSTEMI 38.7 vs 61.3 41.9 vs 58.1 35.5 vs 64.5 0.251
Baseline medication
Prior P2Y12-
inhibitor (%)
17.4 14.4 20.4 0.097
Prior anticoagulant 
(%)
26.9 24 33.3 0.170
Prior MI (%) 29.1 26.8 31.4 0.247
Prior PCI (%) 36,0 34.9 37 0.652
Peri-interventional
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Table 2: Baseline characteristics 
Table 3: Loading characteristics 
3.1.1. Peri-interventional treatment 
Stent 
An intracoronary stent was placed in 351 cases (80%) and only 87 patients (19.8%) 
were not treated via stent. 2.5% received a bare metal stent (BMS) as well as a drug 
eluting stent (DES) and one patient (0.2%) had no documentation of treatment option. 
Sealing system (%) 43.7 42.7 46 0.517
Stent (%) 80 76.7 87.1 0.011
BMS (%) 12.5 11.7 14.4 0.426
DES (%) 64.9 62.7 69.8 0.147
Study cohort 
n = 439
Cohorts depending on 
bleeding occurrence 
p-value
Control group 
n = 300
Event group 
n = 139
Baseline 
characteristics
Baseline loading 
characteristics
Patients  
n = 439
Cohorts depending on 
bleeding occurrence 
p-value
Control group  
n = 300
Event group 
 n = 139
Clopidogrel (%) 80.9 84 74.1 0.014
Ticagrelor (%) 14.4 11.3 20.9 0.008
Prasugrel (%) 4.8 4.7 5 0.018
New ADP-antagonist 16.9 13.7 24.2 0.017
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Access site 
With 431 patients (98.2%), the majority was accessed via femoral artery for the 
procedure, whereas only three patients (0.7%) were done by radial artery access. In the 
case of four patients (0.9%) the access way was not known and one person (0.2%) was 
done by radial and by femoral artery. 
Sealing system 
A protective sealing system used at puncture site to prevent bleeding events was 
implanted post-interventional in 192 patients (43.7%). 245 patients (55.8%) were not 
treated with a sealing system and for two patients (0.5%) the status was unknown. Out 
of all sealing systems being used, 37.1% of all patients received AngioSeal, 4.8% were 
treated with ExoSeal, 1.4% with ProGlide. 0.5% received a TR-band following 
intervention via radial artery. 
Control group versus event group 
Stent 
76.7% received a stent implantation of any kind within the control group and 87.1% 
within the event group. A significantly higher percentage of patients out of the event 
group compared to the control group received treatment via stent, which showed to be 
true for both stent types. 14.4% versus 11.7% of patients were treated with BMS and in 
69.8% versus 62.7% of the patients a DES was placed. Only 12.2% of patients in the 
event group were not receiving a stent during PCI, but 23.3% of the control group were 
not treated by stent implantation. The data shows that there was a significantly higher 
rate of patients treated via stent of the coronary artery within the event group (p = 
0.011), suggesting a higher risk of bleeding, when using a stent. This was true for BMS- 
and DES-implantation. On all the patients being treated via stent, the event group makes 
up about 34.5%, which is not significantly larger than the proportion made up by this 
cohort on all the patients (31.6%). The same can be shown for DES and BMS 
implantation separately, suggesting no significant increase of risk in bleeding for 
patients being treated with stent implantation. 
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Sealing system 
Comparison shows that a sealing system has been used more frequently, but not 
significantly so, throughout the event group with a total of 64 patients (46%) compared 
to 128 patients (42.7%) in the control group (p = 0.517). This distribution was true for 
all sealing system, except for the use of ProGlide with very small patient numbers 
respectively.  35.7% of the patients in the control group were treated via AngioSeal and 
4.7% with ExoSeal versus 40.3% and 5% in the event group. Out of the control group, 
56.7% compared to only 53.9% of the event group were not treated with a protective 
system following intervention. 
Paradoxically, the amount of usage of an angio sealing system, used to protect bleeding 
after PCI, was more frequent among patients suffering a bleeding. This may be 
explained by the fact, that those patients were already considered at greater risk of a 
bleed and therefore were more frequently treated with protective sealing systems. The 
proportions made up by both cohorts on all sealing systems used, does not seem to vary 
significantly from their proportion on the study cohort (33.3% versus 31.6%). 
3.2. Bleeding complications 
3.2.1. Overall bleeding events 
Out of all 439 patients included in the study 139 (31.6%) suffered a documented 
bleeding event after PCI, making up the event group. 300 patients (68.3%) did not show 
any signs of a post interventional bleeding complication (control group). (Fig. 1) 
Fig. 1: Proportion of occurred bleedings of entire study cohort. 
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Bleeding severity 
The event group consisted of 84 patients that were classified as TIMI minimal, 47 as 
TIMI minor and 7 as TIMI major bleedings. One patient was not classified via TIMI 
bleeding score. (Fig. 2) 
Classified by the GUSTO-Score, 123 patients suffered a mild bleeding, seven were 
classified as moderate- and again seven as severe bleeding complication. (Fig. 3) Using 
the BARC Classification, 78 patients suffered a type one bleeding, 43 a type two 
bleeding, eight patients suffered a type 3a bleeding, four patients a typ 3b bleeding, 
three suffered a type 3c bleeding and one patient a type four bleeding. There was no 
occurrence of type five bleeding throughout the entire study cohort. Altogether, 16 
patients had a major bleeding event, defined by us as being classified BARC three or 
above. (Fig. 4) 
Fig. 2: TIMI    Fig. 3: GUSTO Fig. 4: BARC 
Fig. 2,3 and 4: Proportion of bleeding severity (%) on all bleeding events by classification score used. 
Out of all patients of the event group, major bleedings made up 5.1%, when classified 
via TIMI or GUSTO and 11.5%, when classified via BARC. There was a significant 
(two to three fold) higher initially calculated mean major-bleeding risk for the entire 
study population, when compared to the observed occurrence of major bleeding events 
after intervention (4.7% and 6% risk with ACUITY and CRUSADE respectively 
vs.1.6% major bleeding events when classified TIMI/GUSTO, p = 0.011). There was no 
significant difference when compared to BARC-classification of major bleeding (3.6%, 
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p = 0.114). When comparing initial bleeding risk stratification with occurred bleeding 
events for the event group only, there is no significant difference for major bleeding, 
when classified by TIMI/GUSTO, but a significant difference, when evaluated via 
BARC (p =  0.607 and p = 0.050 for BARC). (Fig. 5) 
Fig. 5: Calc. risk vs. occurrence of major bleed (p=0.607 and p=0.050). 
Clopidogrel versus new ADP-antagonists 
355 patients (80.9%) received clopidogrel and 84 patients (19.1%) received one of the 
newer P2Y12-inhibitors, including either ticagrelor or prasugrel. 
When looking at differences between the amounts of occurred bleedings after PCI, the 
newer P2Y12-inhibitors were associated with higher risk of overall bleeding events in 
comparison with clopidogrel. (44.3% vs. 28.2% for the new inhibitors vs. clopidogrel 
respectively, p = 0.017, Fig. 6). This difference was driven by minor bleedings (TIMI 
minimal or minor 40.5% vs. 27.9% for new inhibitors vs. clopidogrel respectively, p = 
0.05, TIMI major 1.4% vs. 2.4%, p=ns) 
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 Fig. 6:  Total bleedings clopidogrel vs. new P2Y12-inhibitors (p=0.017). 
Timing of P2Y12-inhibitor administration 
The cohort, which received a pre-PCI loading only, included a total number of 232 
patients (52.8%). 26 patients (5.9%) only had a P2Y12-Inhibitor as part of their pre-
medication, 136 patients (31%) received a loading dose prior to PCI as well as at the 
time of PCI and 45 patients (10.3%) used a P2Y12-inhibitor as pre-medication as well 
as receiving a loading dose during PCI. We did not find significant differences 
concerning overall bleeding complications according to different loading strategy. There 
were 32.8%, 42.3%, 25.7% and 37.8% bleeding complication in patients with pre-PCI 
loading, pre medication only, pre-PCI with second loading and pre medication with 
second loading respectively. (p = 0.211, Fig. 7) 
Fig. 7: Rate of bleeding events depending on timing of loading (p = 0.211). 
46
B
le
ed
in
g 
ev
en
t (
%
)
0 %
12 %
23 %
35 %
46 % Pre-PCI only
Pre-medication only
Pre-PCI + at PCI 
Pre-medication + at PCI 
Overall bleeding
B
le
ed
in
g 
ev
en
t (
%
)
0 %
12 %
23 %
35 %
46 %
Clopidogrel
Newer inhibitors
Evaluating the data regarding TIMI major bleedings alone did not show a significant 
difference. There were 6.6%, 0.0%, 5.9%, 0.0%, TIMI major bleeding complication in 
patients with pre-PCI loading, pre medication only, pre-PCI with second loading and pre 
medication with second loading respectively. (p = 0.166; Fig. 8). 
Fig. 8: Proportion of patients of loading categories suffering a TIMI major                     
bleeding (p = 0.166). 
3.3. Risk factors 
3.3.1. Bleeding risk scores 
CRUSADE 
The mean CRUSADE risk score for the entire study population was calculated at 26.5 
(CI 25.0 - 28.0), being considered a low-risk category with a risk of in-hospital major 
bleeding of approximately six percent. Evaluation of the CRUSADE risk score for each 
cohort individually showed, that the control group had a calculated mean CRUSADE 
score of 24.6, whereas the event group averaged a higher mean CRUSADE score of 
29.4. Accordingly, both cohorts would also individually be classified as low risk, but 
ranging from approximately 5.7% risk of in-hospital major bleeding for the control 
group to about 6.5% risk for the event group. (Fig. 9) 
ACUITY 
The mean ACUITY risk score was calculated at 14.8 points (CI 14.0 - 14.6), which is 
considered a moderate risk category with an expected non-CABG major bleed within 30 
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days of approximately 4.7%. The mean ACUITY risk score for the control group was 
13.9 points resulting in a classification of moderate risk with a risk of major bleeding of 
about 4.7%. The event group showed to be a high risk classification, with a mean 
ACUITY risk score of 16.5 points, translating to a risk of major bleed of approximately 
5 to 6% within 30 days. (Fig. 9) 
Fig. 9: Bleeding risk by CRUSADE and ACUITY and occurred major bleeding                      
(%) for both cohorts. 
3.3.2. ADP-Multiplate 
Out of all 439 patients included into the study, 95.9% received an ADP-multiplate 
analyzing to further determine the platelet function in regard to ADP-receptor 
interaction, whereas 18 patients (4.1%) did not receive a measurement of their platelet 
function via multiplate. The overall mean ADP test for all 421 patients was calculated at 
27.2 U. Patients with bleeding events showed significant higher platelet inhibition (14.6 
U vs. 20.2 U for patients with and without bleedings respectively, p = 0.012) at time of 
steady-state (Fig. 10). The data shows a significant lower mean ADP-multiplate test in 
patients suffering a bleeding event compared to patients without any bleeding events, 
suggesting a low ADP-test to be a significant predictor for the increase in risk of 
adverse bleeding events. 
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Fig. 10: Mean ADP in control vs. event group in steady state (p = 0.012). 
P2Y12-inhibitor depending mean ADP 
Patients receiving a new ADP-Antagonists showed a significant lower ADP-test 
compared to patients receiving clopidogrel. (23.0 U and 30.6 U respectively, p= 0.017; 
Fig. 11).  
Fig. 11: ADP-Multiplate for clopidogrel vs. new ADP-antagonists (p = 0.017). 
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3.3.3. Risk factor variables 
The following five variables showed to be significant predictors of an increase in 
adverse bleeding events in NSTE-ACS patients following PCI and P2Y12-inhibitor pre-
treatment (p < 0.1; table 4) and were included in a multivariate analysis: Age at time of 
intervention, usage of newer P2Y12-inhibitor, diabetes mellitus, reduced renal function 
(GFR < 60%) and the ADP-multiplate data.  
In the multivariate analysis only the ADP-multiplate and diabetes mellitus remained a 
significant predictor of bleeding events (table 5). Age, usage of newer P2Y12-inhibitor 
and decreased renal function were no longer significant.  
Table 4: Statistical significance of risk factor variables. 
B
Odds 
ratio
95% C.I.for EXP(B)
PLower Upper
Age at intervention 0.028 1.028 1.010 1.047 0.003
Gender 0.273 1.314 0.854 2.019 0.214
BMI (kg/m2) 0.013 1.013 0.975 1.052 0.507
New ADP-inhibitor 0.593 1.810 1.110 2.951 0.017
IAP versus NSTEMI 0.243 1.275 0.842 1.932 0.251
Hypertension 0.099 1.104 0.652 1.869 0.714
D.M. 0.383 1.466 0.958 2.244 0.078
HLP 0.077 1.081 0.721 1.620 0.708
GFR (CockroftGault) 0.005 0.995 0.990 1.000 0.060
Renal insufficiency 
(GFR < 60%) 0.484 1.623 1.045 2.521 0.031
Anticoagulants 0.460 1.584 0.821 3.054 0.170
ADP-Multiplate 0.033 0.968 0.994 0.993 0.012
MACE 0.183 1.201 0.629 2.293 0.578
Heart insufficiency 
(LVEF < 55%) 0.240 1.271 0.752 2.147 0.371
Sealing system used 0.134 1.143 0.763 1.712 0.517
prior MI 0.261 1.298 0.835 2.016 0.247
Secondary loading 0.195 1.215 0.809 1.825 0.348
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Table 5: Multivariate analysis 
Other risk factors tracked did not show to be significant predictors for post 
interventional bleed in NSTE-ACS patients after ADP-antagonists pretreatment (p > 
0.1), including: gender, BMI, UAP vs. NSTEMI, hypertension, HLP, use of 
anticoagulants beforehand, MACE, heart insufficiency defined as LVEF below 55%, the 
usage of a sealing system after intervention, prior MI and administration of a secondary 
loading dose in patients (table 4). 
3.4. Follow-up 
3.4.1. Mortality risk scores 
The mean GRACE mortality score was 96.7 (CI 94.2 - 99.1), which is considered a low 
risk category with an in-hospital mortality of below one percent and an intermediate risk 
category for a six months post-discharge mortality of three to eight percent. When 
calculating the risk score for each subgroup individually, it showed a score of 100.1 for 
the event group and a risk score of 94.5 for the control group. Both cohorts would still 
be classified as low risk category for in-hospital mortality and intermediate risk 
category for six-months post discharge mortality for NSTE-ACS patients. 
The mean TIMI risk score was at 2.9 (CI 2.8 - 3.0) giving an approximately 13% risk of 
all-cause mortality, new or recurrent MI or severe recurrent ischemia at 14-days. 
Calculating the TIMI risk score for each cohort individually shows a score of 3.1 for the 
control group and a score of 2.8 for the event group. 
B
Odds 
ratio
95% C.I.for EXP(B)
PLower Upper
Age at intervention 0.004 1.004 0.974 1.034 0.804
New ADP-antagonist 0.318 0.727 0.315 1.682 0.457
Diabetes mellitus 0.827 2.287 1.216 4.300 0.010
Renal insufficiency 0.473 1.604 0.705 3.654 0.260
ADP-Multiplate 0.028 0.972 0.947 0.998 0.034
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Comparing the calculated mean risk of mortality at time of hospitalization with the 
overall mortality at the three months follow-up showed a lower percentage of death than 
expected with 1.6% versus 3-8% in the GRACE score and 13%, including the risk of 
other primary end points, in the TIMI risk score (Fig. 12). 
Fig. 12: Calculated mortality risk versus observed mortality at three months. 
3.4.2. Overall outcome 
The three months follow-up concluded that out of 439 patients, 82% of the patients 
suffered no further event. 79 patients (18%) reported one of the primary endpoints as 
defined before. 1.4% suffered a stroke and 0.2% a TIA, 6.6% were re-hospitalized, 
because of an ACS, 0.5% were treated for stent thrombosis, 7.7% had to receive a re-
PCI and 1.6% had died within the given time span. No patients were completely lost to 
follow-up (Fig. 13). 
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  Fig. 13: Event rates at three months follow-up of the entire study cohort. 
3.4.3. Timing of P2Y12-inhibitor 
25% of patients in the control group and 23.5% in the event group receiving a loading 
dose of an ADP-antagonist at time of PCI additionally to their prior medication had to 
be re-hospitalized because of a recurrent ACS. This proportion is significantly higher 
than the proportion of recurrent ACS on all patients, being 6.6%. It is also higher than 
the calculated mean TIMI risk score for primary endpoints of about 13%, which 
includes the risk of MI (Fig. 14 and 15). There were two patients in the loading at PCI + 
prior medication group and none in the other loading groups that suffered an ACS 
within the first 5 days after initial PCI, which showed to be significant (p = 0.001). 
Fig. 14: Follow-up depending on loading time in the control group. 
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 Fig. 15: Follow-up depending on loading time in the event group. 
3.4.4. Control group versus event group 
In the control group six patients suffered a stroke within three months making up 2% 
and one patient suffered a TIA (0.9%), whereas in the event group none of the patients 
stated to have had a stroke, nor a TIA. In the control group three patients died, making 
up one percent, whereas four patients (2.9%) out of the event group have died during 
the same time interval (p = 0.144). The higher percentage of death within this cohort 
correlates with the higher pretreatment mortality risk calculated via GRACE and TIMI 
risk score (Fig 16). However, in both cohorts and in all patients the percentage of death 
is lower than the mortality risk that was initially determined. The data also states no 
significant difference in the likelihood of occurrence of primary endpoints at the three 
months follow-up between both groups (p = 0.792).  
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 Fig. 16: Rate of primary endpoints at three months follow-up. (p = 0.792) 
3.4.5. Clopidogrel versus new ADP-antagonists 
Of the 355 patients loaded with clopidogrel, 1.4% suffered a stroke or TIA, 5.4% were 
re-hospitalized because of ACS, 0.5% suffered a stent thrombosis and 7% needed a 
revascularization. In the group of 84 patients loaded with one of the new P2Y12-
inhibitors the numbers were 2.4%, 11.9%, 0% and 10.7% respectively. It shows no 
significantly higher risk for the combined ischemic endpoints (p = 0.640), but for ACS 
occurrence alone a significant higher risk in the new P2Y-12-inhibitor group (p = 0.028; 
Fig. 17). 
Fig. 17: Rate of primary endpoints at three months follow-up in comparison between 
clopidogrel and new P2Y12-inhibitor. (p= 0.640 (combined), p = 0.028 (ACS alone)) 
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4. Discussion 
4.1. General bleeding outcomes 
The analyzed data showed that post interventional bleeding, with an occurrence rate of 
32% still is a significant adverse complication in NSTE-ACS patients undergoing PCI. 
Most bleeding events were located at puncture site and classified as being minor. Only 5 
to 11.5%, depending on the classification score used, of the documented bleeding events 
were classified as being major. Those numbers are comparable to the data presented by 
earlier studies [26, 56, 29] and lower than the initially calculated risk of major bleeding 
throughout the study population. The overall bleeding rate of 32% seemed to be a little 
higher than described in most previous studies [29]. This may be the case, because of a 
more detailed documentation and retrospective research in regard to minor bleeding 
events, since most described minor bleedings were small hematomas at puncture site. 
The results show a similar distribution of bleeding severity among TIMI and GUSTO 
classification, but a more than two times higher rate of „major“ bleeding, when 
classified via BARC (1.6% for TIMI and GUSTO versus 3.6% for BARC). This may be 
the result of the more detailed classification that is made by BARC, making up more 
categories and initially avoiding a description as major or minor, but instead to number 
the categories with increasing severity. We chose to define a BARC three score or 
higher as being major, which may have led to a higher percentage of major bleeding, 
when classified via BARC, as compared to GUSTO and TIMI.   
The study shows that bleeding events after percutaneous intervention is a common and 
potentially serious complication, that needs to be taken into consideration before 
performing PCI. The possible negative influence of bleeding events on overall mortality 
has been stated by other studies and described in the introduction. These findings on a 
worse outcome after occurred bleeding, however, could not be supported by the analysis 
of the three months follow-up in this study as shown below.  
Overall the data supports the need for better evaluation tools for the risk of bleeding 
complications before undergoing PCI or receiving a P2Y12-inhibitor and preferably at 
point of admittance in order to further decrease these adverse complications in the 
future.  
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4.2. Risk factor analysis 
Primary aim 
After evaluation of sixteen different patient characteristics, we were able to identify five 
variables to be significant predictors of bleeding events following PCI in NSTE-ACS 
patients. These variables included: age at intervention, diabetes mellitus, ADP-
Multiplate analysis data, renal insufficiency with a GFR < 60% and the usage of a 
newer P2Y12-inhibitor in form of ticagrelor or prasugrel. After multivariate analysis 
only the variables diabetes mellitus and the measured ADP-multiplate data stayed 
significant. The other three predictors mentioned did not stay significant. 
The measured platelet function via ADP-multiplate analyzer was able to show that 
patients, who suffered a post interventional bleeding event had significantly higher 
platelet inhibition. This result sustains that a higher platelet inhibition correlates well to 
a higher risk of adverse bleeding events after PCI and could be used to evaluate patient 
risk. An ADP-multiplate testing is a rather time consuming process, which does not 
seem to be useful to wait on for emergency patients presenting with NSTE-ACS. It 
could however be analyzed at point of admission, before treatment with P2Y12-
inhibitors and then be used after further evaluation for possible preventive measures 
during or after PCI.  
Unfortunately, the study was not able to state enough significant risk factors of post 
interventional bleeding occurrences in NSTE-ACS patients to create receiver operating 
characteristics (ROC) curves to compare to the existing ACUITY and CRUSADE score. 
Furthermore we were not able to create the bleeding risk stratification score as 
anticipated by this study, because of the missing significance of risk factors and their 
influence on bleeding events. We can only conclude five risk factors that showed to be 
significant, of which only two remained significant after multivariate analysis being 
diabetes mellitus and low ADP-multiplate scores. 
The study only included a total of 439 patients, which may be too small of a study 
population to create a significant risk profile for patients. Risk factors described by 
other studies, like the baseline use of anticoagulants, were hardly represented within this 
study group. Only 41 patients were using anticoagulants as baseline medication, which 
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showed to have a significance level of 0.170 in our statistical analysis. We believe that 
those variables, among others, might show a bigger impact on bleeding risk than 
represented by this study population, and could be used as starting point for further 
studies and hypotheses. Risk factors of bleeding events previously described by 
CRUSADE and ACUITY [40, 61], like advanced age, female sex, signs of CHF and 
prior MI did not hold up to be significant throughout our data analysis of NSTE-ACS 
patients.We believe that since CRUSADE and ACUITY were designed in times of 
different therapy strategies we do need further investigation to create better risk 
stratification for todays patients and treatment options. 
Secondary aim 
The comparison of different pre-treatment P2Y12-inhibitor loading times in regard to 
post interventional bleeding occurrences in NSTE-ACS patients showed that none of the 
collected data was able to state a significant correlation. Therefore the findings of the 
study suggest, that the timing has no significant impact on the likelihood of a bleeding 
event. This showed to be the case regardless of the severity of the evaluated bleed. 
Therefore, according to our data, a pretreatment loading strategy has no significant 
impact on the adverse events after PCI of the NSTEMI patient. This showed to be the 
case in our collective of patients, which was mainly treated with clopidogrel, less often 
with ticagrelor. In difference to the ACCOAST-PCI trial, we saw hardly any use of 
prasugrel in our collective, so that we can make no further statement to underline or 
contradict the findings of the ACCOAST trial, that showed no benefits, but an increase 
in adverse bleeding events with prasugrel-pretreatment in NSTEMI patients.  Given that 
the correlation was only analyzed for different timings all in regard to pre-treatment 
loading options and not in comparison to a loading strategy at the time of PCI only, we 
believe that further studies may be necessary to compare an overall pretreatment 
strategy to a loading strategy at time of PCI. So far the best possible timing for a 
P2Y12-inhibitor treatment is still not proven and remains uncertain for incoming NSTE-
ACS patients.  
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In regard to the kind of P2Y12-inhibitors being used we were able to show, that the 
patients treated by newer ADP-antagonists, ticagrelor and prasugrel, showed to have 
significantly higher platelet inhibition, when compared to clopidogrel. Also there was a 
significant higher rate in bleeding, when using one of the newer ADP-antagonists with 
42.9% versus 29.3%, when receiving clopidogrel. The use of different P2Y12-inhibitor 
could not be proven significant in a multivariate analysis. The data from the multiplate 
analysis (platelet inhibition) however still showed to be significant throughout the 
multivariate analysis and may be a starting point for further investigation of the risk in 
the new P2Y12-inhibitors. After adjusting for severity categorization via GUSTO and 
TIMI, where 5.6% of the patients receiving a newer ADP-antagonist and suffering a 
bleeding event were classified as being a TIMI major bleed. In the clopidogrel group, 
the proportion of TIMI-major bleeds made up 4.9% out of all bleeding events 
respectively. Since we expected and stated a higher occurrence rate in bleeding, when 
using one of the newer ADP inhibitors, after showing a significant lower ADP-
measurement, we would explain the missing significance in the multivariate analysis of 
the data by the small patient numbers treated with one of the newer P2Y12-inhibitors 
throughout the study. Throughout the time span of intervention taken place, most of the 
patients were still loaded with clopidogrel, instead of one of the newer ADP-
antagonists. After the pivotal studies TRITON-TIMI-38 in 2007 [68] for the use of 
prasugrel versus clopidogrel and the PLATO-trial in 2009 [66] for the use of ticagrelor 
versus clopidogrel the distribution between these P2Y12-inhibitors used has shifted. 
Both trials showed a reduced ischemic event rate in patients with ACS for the use of 
ticagrelor / prasugrel versus clopidogrel. The increasing use of newer P2Y12-inhibitors 
and has not been taken into account in any of the bleeding risk scores available so far 
and most studies have been performed on populations mostly consisting of cohorts 
using clopidogrel. This, unfortunately, has also been the case for this study. Therefore 
we believe this topic to be of interest for further studies with a bigger study population 
tested for better comparison. 
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4.3. Follow-up 
The overall occurrence of tracked primary endpoints after three months was with a total 
of 18% lower than the calculated risk scores anticipated.  
The follow-up data presented no significant difference in the occurrence of primary 
endpoints between both study groups. Therefore, in contrast to earlier studies, we 
cannot conclude that occurred bleeding events in NSTE-ACS patients have a negative 
impact on the risk of primary endpoints at three months. There was only a slightly 
higher rate of stroke and TIA (2.9% in the control group versus 0% in the event group) 
in patients not suffering a postinterventional bleeding event. This data would be 
explainable by a lower rate of platelet inhibition throughout the control group, which 
has also been shown by the ADP-Multiplate measurements. A lower inhibition of 
platelet aggregation leads to a higher risk of ischemic events. Other cofounders, like 
post interventional P2Y12-inhibitor treatment and patient compliance were not tested 
and would also affect the risk of further ischemic events. The higher, but not significant, 
mortality rate in the event group of 2.9% versus 1% in the control group tracks well 
with the higher initially calculated risk of mortality. It could be due to a higher risk 
profile and comorbidities by these patients. 
It did show a significant higher occurrence of ACS within the subgroup of patients 
receiving an additional loading dose to their preexisting treatment with an ADP-
antagonist. This result seems paradox, considering that the loading with an ADP-
antagonist is supposed to reduce the risk of primary ischemic endpoints, but may be a 
confounder. It is possible that especially patients with a higher initial risk of ischemic 
events were given a second loading dose. These findings may also be explained by the 
overall small number of only 45 patients within this subgroup and the overall small 
patient numbers of the study. 
Patients treated with a newer ADP-antagonist showed to make up a higher proportion on 
recurrent PCI, ACS and stroke after three months compared to the clopidogrel-group, of 
which only the occurrence rate in ACS stayed significant (p = 0.280). These findings 
also seem paradox, since the newer P2Y12-inhibitors have a higher effect on platelet 
inhibition, which could also be shown in the multiplate data. These results may again be 
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explained by the effect as a confounder, where the patients receiving the newer ADP-
antagonist might have shown the higher initial risk for ischemic events. And again this 
subgroup consisted of small numbers of patients being treated with one of the newer 
inhibitors throughout the study group. Also the longterm treatment with P2Y12-
inhibitors, preventing ischemic events, as well as patients compliance were not further 
taken into account.  
4.4. Outlook 
This study did show that bleeding complications are still a common problem following 
PCI and that ADP-multiplate analysis is a valid tool to evaluate platelet function and the 
risk of bleeding. Unfortunately we were not able to create a scoring system to classify 
NSTE-ACS patients at point of admission depending on their individual risk of 
bleeding. Other than the ADP-multiplate data and diabetes mellitus, the taken risk 
variables did not stay significant after multivariate analysis. Further studies with a 
bigger study population may be necessary to evaluate more risk factors and especially 
the role of newer P2Y12-inhibitors on occurring bleeding complications. Also the best 
timing of administration of the P2Y12-inhibitor is still unknown and may be subject for 
further studies. 
We believe that the two bleeding risk scores being used, CRUSADE and ACUITY, both 
have their individual weaknesses, when applied to nowadays NSTE-ACS patient 
population. They both derived from a time with a bigger emphasis on bivalirudine or 
GPI-usage and a limited evaluation of different P2Y12-inhibitors and their timing of 
administration in regard to PCI treatment. Therefore, we believe a more accurate risk 
score, adapted to the treatment options of our time is vital in the evaluation of the risk of 
bleeding in NSTE-ACS patients at time of admission. This will help us in deciding on 
the right treatment option and timing and reduce the occurrence of adverse 
complications doing so. To create such a score, further, more adapted studies with 
bigger study populations will be necessary. 
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5. Limitations 
Over all the study conclude is a retrospective analysis with a small number of patients, 
which limits the extent of the possibility to transfer these results to the general practice, 
but gives an idea of possible starting point for further studies and investigations. 
1) Recall bias 
The case control study design holds the risk of a recall-bias. In this case, especially that 
patients don't accurately recall certain risk factors to the right extent or follow-up data 
gets lost or is not remembered to the right extent. 
2) Selection bias 
Selection bias may occur in form that patients are not equally loaded with the same kind 
of P2Y12-inhibitor or different dosages within the subgroups. Also an exact selection of 
a matched control group is difficult to achieve and may lead to biased results.  There 
was no cohort with loading only at time of PCI as control to the timing of P2Y12-
inhibitor. Within the different risk factors being responsible for a higher risk in bleeding 
we cannot exclude all the confounders that may intervene with these results. There also 
may have been other factors before or after P2Y12-inhibitor treatment and PCI effecting 
the risks of bleeding in patients that are not known to us and have therefore not been 
included.  
3) Different interpretation 
The severity of the bleeding of the patients may have been interpreted differently by 
different doctors, especially when clinical diagnosis seemed sufficient and there was no 
laboratory panel or imaging. Also there may have been a different level of accurate 
documentation of bleedings, which we used to identify and classify the patients with. 
This could lead to missing bleeding events that were not accurately documented. 
4) Follow-up 
In the three months follow-up there may be circumstances for patients to drop out of the 
personal follow-up, for example being unable to get ahold of anymore or simply not 
wanting to be actively participating any longer. Also there may be a recall bias on 
whether there were certain end points taken place, for example not exactly knowing the 
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cause of death or further primary end points in a patient by their relatives being 
questioned. 
5) P2Y12-inhibitors 
There was no difference made between the three P2Y12-inhibitors used, so that there 
might be different outcomes when looking at each one of them individually. A 
possibility of confounding would also be the dosage of ADP-antagonists that was given 
and may vary between patients. We mainly saw the use of clopidogrel 600 mg as a 
loading dose prior to PCI, which may not reflect today routine with an increase in the 
usage of especially ticagrelor and prasugrel, as well. 
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6. Conclusion 
Bleeding events following PCI are still a common complication among NSTE-ACS 
patients. This study was able to show a significant increase in the risk of bleeding for 
increasing inhibition measured via ADP-multiplate and for one of the cardiovascular 
risk factors, being diabetes mellitus after multivariate analysis. Therefore patients with a 
higher platelet inhibition are more likely to suffer a bleeding event after PCI. The 
initially shown increase of bleeding events, when using one of the newer ADP-
antagonists did not stay significant in the multivariate analysis. There was no 
statistically significant increase in risk of bleeding in any of the other risk factors tested, 
nor depending on the timing of loading the patient. Unfortunately, we could not identify 
enough significant risk factors with a correlation to an increased risk in bleeding events 
to create a ROC curve to compare it to the existing ACUITY and CRUSADE risk 
scores. Also the data could not be used to create our own significant risk score to 
evaluate the risk of bleeding in incoming NSTE-ACS patients before treating via PCI, 
as anticipated as primary aim of this study. Following these results the only significant 
way to get a better idea of the bleeding risk of the individual patient would be by ADP-
multiplate analysis, which seems not practical in terms of daily use before treating via 
PCI. 
However, this study only included a small number of patients. Especially, when 
comparing P2Y12-inhibitors used, the group receiving one of the newer inhibitors was 
still very small. The study did show a significant higher platelet inhibition by newer 
P2Y12-inhibitors via ADP-multiplate data, but no significant increase in risk of 
bleeding throughout this subgroup. With nowadays increasing numbers of patients 
treated with one of the newer ADP-antagonists, this unknown role may be subject of 
evaluation in further studies. 
The timing of pretreatment loading seems to have no impact on the occurrence of 
bleeding throughout our study group. Further studies however may compare the risks to 
a loading strategy at time of PCI and take the increased usage of ticagrelor and 
prasugrel into account. 
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Looking at adverse events the study showed a signifiant increase in the occurrence of 
ACS at three months after PCI, when using a newer ADP-antagonist. This paradox 
finding may be a confounder, since patients with higher ischemic risks may be more 
likely to receive one of the newer ADP-antagonists in an overall small subgroup 
receiving ticagrelor or prasugrel. The total end point of ischemic events was a little 
higher in patients receiving one of the new ADP-antagonists, but not significantly so. 
These findings contradict other studies (PLATO and TRITON-TIMI) and may be due to 
the small numbers of patients within these groups. We believe that further studies with 
better subgroups representing todays distribution of P2Y12-inhibitors used are needed 
to evaluate this complex topic better. There was no significant difference found between 
the two study groups or between different loading intervals in regard to ischemic end 
points at the three months follow-up. 
We believe that further studies are necessary to investigate the bleeding risk, different 
loading times and dosages. These studies should consist of patient cohorts representing 
today’s treatment options better, the more frequent usage of new ADP-antagonists, as 
well as the radial access site as primary access site used. With these data we hope a 
better and up to date risk score can be created to evaluate bleeding risk before treatment 
and enable a more personalized strategy. 
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7. Abstract 
Introduction 
This retrospective study was conducted at the university hospital of Tuebingen and 
included NSTE-ACS patients receiving a PCI throughout the years of 2011 to 2014. A 
total of 439 patients was included into study. We divided the cohort into two groups. 
The control group, making up 300 patients without any adverse bleeding event and the 
event group with 139 patients, all suffering a documented post interventional bleeding 
incidence. The primary aim of the study was to evaluate the overall risk for occurrence 
of adverse bleeding events in NSTE-ACS patients following PCI. Secondly we were 
looking to identify a risk profile for NSTE-ACS patients in order to create a score to 
better identify patients at risk for bleed. That again would allow the clinician to 
categorize the patient at time of admission and depending on classification change 
treatment protocols towards more preventive measures to reduce the risk of post 
interventional bleeding events. 
Methods 
We retrospectively analyzed 16 different factors to identify risk variables significantly 
associated with a higher risk in adverse bleeding events in NSTE-ACS patients 
undergoing PCI. Additionally we evaluated different times of loading and compared 
clopidogrel to one of the newer P2Y12-inhibitors in regard to bleeding events and 
occurrence of MACE after three months of hospitalization. Each patient got 
measurements of their ADP-inhibition via ADP-multiplate analysis. A three months 
follow-up was done with all patients. 
Results 
Out of all the variables tested five risk factors proved to show significant, including: 
diabetes mellitus, ADP-multiplate scores, renal insufficiency (GFR < 60%), age at 
intervention and the usage of a new P2Y12-inhibitor. In the multivariate analysis the 
following two variables persisted to be significant: the ADP-multiplate data and 
diabetes mellitus. The other three variables unfortunately did not stay significant. 
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There was no significant difference between clopidogrel and new ADP-antagonists in 
regard to bleeding events. Also there was no significant difference between both study 
cohorts in the risk for ischemic events at the three months follow-up. It did show a 
significant higher risk for ACS after five days and three months for patients with an 
ADP-antagonist in their prior medication, who received an additional loading at time of 
PCI.  
Discussion 
We were able to show that postinterventionel bleeding still states a risk after PCI, even 
though it did not show a significant difference for the midterm outcome at the three 
months follow-up. The ADP-multiplate seems to bee a valid tool to measure the amount 
of platelet inhibition and the risk of bleeding, but is not clinically useful for the ad hoc 
therapy decision. Therefore we believe further studies are necessary to create a risk 
scheme for a more individualized treatment strategy for todays NSTE-ACS patients. 
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8. Zusammenfassung 
Einleitung 
Die retrospektive Studie wurde im Rahmen der TuePIC-Studie der Abteilung 
Kardiologie des Universitätsklinikums Tübingen durchgeführt und involvierte 
insgesamt 439 NSTE-ACS Patienten, welche mittels PCI behandelt worden. Wir 
bildeten zwei Kohorten, die Kontrollgruppe, bestehend aus 300 Patienten, welche alle 
kein Blutungsereignis hatten und die Eventgruppe mit 139 Patienten mit 
dokumentiertem postinterventionellem Blutungsereignis.  
Das primäre Ziel der Studie war es zunächst das Gesamtrisiko für das Eintreten von 
Blutungsereignissen nach PCI in NSTE-ACS Patienten besser abzuschätzen. Vor allem 
aber dann verschiedene Patientenvariablen auf deren Zusammenhang mit einem 
erhöhten Blutungsrisiko zu analysieren um ein Risikoprofil erstellen zu können. Mit 
diesem Risikovariablen erhofften wir uns ein Score zu erstellen, mit dessen Hilfe es 
möglich ist Patienten bei Aufnahme, in Bezug auf ihr individuelles Blutungsereignis, 
kategorisieren zu können und dann nach Bedarf das Therapieprotokoll anpassen zu 
können, um postinterventionelle Blutungen zu verhindern. 
Methoden 
Wir haben 16 verschiedene Variablen getestet um einen signifikanten Zusammenhang 
mit einem erhöhten Blutungsrisiko in NSTE-ACS Patienten nach PCI zu untersuchen. 
Außerdem haben wir verschiedene Loadingzeitpunkte, sowie den Vergleich zwischen 
der Gabe von Clopidogrel gegenüber einem den neuen P2Y12-Inhibitoren in Bezug auf 
ein erhöhtes Blutungsrisiko und dem auftreten von MACE im follow-up nach drei 
Monaten evaluiert. Alle Patienten erhielten eine Messung der ADP-Inhibierung via 
ADP-Multiplate. Diese Daten wurden ebenfalls in Bezug auf das Blutungsrisiko 
evaluiert. Es erfolgte eine dreimonatiges follow-up mit allen Patienten.  
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Ergebnisse 
Aus allen getestet Variablen konnten wir fünf Faktoren finden, die sich als signifikant 
herausstellten. Dazu gehörten: Alter bei Intervention, Diabetes Mellitus, Nieren-
insuffizienz (GFR < 60%), die ADP-Multiplate Daten und die neuen P2Y12-Inhibitoren. 
In der Multivariante Analyse persistierten nur die ADP-Multiplate Daten und Diabetes 
mellitus signifikant. Die weiteren Variablen zeigten sich nicht signifikant. Im follow-up 
zeigte sich ein signifikant erhöhtes Auftreten von ACS innerhalb von 5 Tagen und 3 
Monaten bei Patienten die eine Vormedikation mit einem P2Y12-inhibitor erhielten und 
zudem während der PCI erneut geloaded wurden. Ansonsten gab es keine signifikanten 
Unterschiede während der follow-ups. 
Diskussion 
Postinterventionelle Blutungsereignisse sind weiterhin eine häufige Komplikation in 
NSTE-ACS Patienten. Diese Studie konnte einen signifikanten Zusammenhang 
zwischen den ADP-Multiplate Daten und dem Vorliegen eines Diabetes mellitus mit 
einem erhöhten Risiko für postinterventionelle Blutungen aufzeigen. Leider war es uns 
auf Grund der fehlenden Signifikanz weiterer Risikofaktoren nicht möglich den 
angestrebten Risikoscore zu entwickeln, welcher die bessere Einschätzung des 
Blutungsrisikos des Patienten bei Aufnahme ermöglicht.  
Bezüglich unserer zweitrangigen Hypothesen konnten wir keinen signifikanten 
Unterschied zwischen den verschiedenen Loadingzeitpunkten und dem post-
interventionellem Blutungsrisiko aufweisen. Da wir nur Loadingzeitpunkte vor PCI 
untersuchten, ist ein Vergleich zum Loading während PCI eine mögliche Thematik in 
späteren Studien. 
Der Vergleich zwischen Clopidogrel und den neuen P2Y12-Inhibitoren zeigte eine 
signifikant höhere Einschränkung der Plättchenfunktion im ADP-Multiplate. Es konnte 
aber in der Studie kein signifikant erhöhtes Blutungsrisiko der Gruppe mit neuen 
P2Y12-Inhibitoren gezeigt werden. Da diese Gruppe in der Studie sehr klein war, wird 
dies ein Thema für folgende Studien sein, um den Einfluss, der immer häufiger 
verwendeten, neueren P2Y12-Inhibitoren auf das Blutungsrisiko zu untersuchen.  
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Das vermehrte Auftreten von ACS in der Patientengruppe mit P2Y12-inhibitor 
Vormedikation und Loading während der PCI sehen wir am ehesten als cofounder und 
bedingt durch die geringe Studienpopulation und noch geringere Subgruppengröße. 
Es werden weitere Studien nötig sein, um das Risiko für Blutungen, vor allem in 
Anbetracht der neuen Therapiestrategien, wie z.B. neue ADP-Antagonisten und radialer 
Zugang, der NSTE-ACS Patienten zu beurteilen und eine aktuellere Möglichkeit der 
Risikoerfassung darzustellen um eine personalisierte Therapie möglich zu machen. 
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